Isogenica Enters into Research and License Agreement with Wyeth
CAMBRIDGE, England,1st June 2007: Isogenica Ltd, today announced that it has entered into a research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE).
Under the terms of the agreement, Isogenica will use its CIS display technology to select therapeutic peptide candidates to an unspecified number of Wyeth targets. The company will receive research fees and milestone and royalty payments for the development and commercialization of any products resulting from the collaboration.
Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.
"We look forward to building a strong and long lasting relationship with Wyeth and in assisting them with their therapeutic discovery activities" said Dr. Kevin FitzGerald, Isogenica's CEO. "We believe that peptides, and especially those discovered and matured for enhanced in vivo performance using CIS display technology, represent a very rich source of compounds for therapeutic and other in vivo applications."
Notes to editors
Isogenica was formed in December 2000 to develop and commercialize innovative in vitro molecular evolution technologies. The company has its research facility at the Babraham Research Campus, Cambridge UK.
Isogenica's core technology, CIS display, can be applied to the discovery of new antibody, peptide and polypeptide drug candidates, to the discovery of high specificity diagnostic compounds and to the isolation of target validation and other research reagents, purification reagents and environmental detection reagents.
Posted: June 2007